Table 3 Characteristics of migraine in patients with and without metabolic syndrome
Migraine patients with metabolic syndrome (n = 13) | Migraine patients without metabolic syndrome (n = 17) | P-value | ||
|---|---|---|---|---|
Attack duration in hours [median (IQR)] | 12 (8- 17.5) | 12 (7.5–12) | 0.259 1 | |
Aura [n (%)] | 2 (15.4%) | 5 (29.4%) | 0.368 2 | |
Autonomic manifestations [n (%)] | 1 (7.7%) | 1 (5.9%) | 0.844 2 | |
Allodynia [n (%)] | 5 (38.5%) | 4 (23.5%) | 0.367 2 | |
MIGSEV Scale [median (IQR)] | Intensity | 3 (2- 3.5) | 3 (2–3) | 0.807 1 |
Disability | 3 (2–3) | 3 (2–3) | 0.657 1 | |
Tolerability | 2 (1.5–2.5) | 2 (1- 2.5) | 0.82 1 | |
Nausea | 2 (1.5- 4) | 2 (1–3) | 0.529 1 | |
Total score | 3 (1.5-3) | 2 (1–3) | 0.26 1 | |
HIT-6 total score [median (IQR)] | 63 (48–64) | 59 (47- 62.5) | 0.628 1 | |